Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 3
2006 2
2007 3
2008 1
2009 4
2010 7
2011 9
2012 14
2013 13
2014 9
2015 13
2016 24
2017 28
2018 39
2019 54
2020 54
2021 54
2022 59
2023 48
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean inotuzumabozogamicin (5 results)?
Inotuzumab Ozogamicin.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 29999985 Free Books & Documents. Review.
No information is available on the clinical use of inotuzumab ozogamicin during breastfeeding. Because inotuzumab ozogamicin is a large protein molecule with a molecular weight of 168,000 Da and its active metabolite is 97% plasma protein bound, the am …
No information is available on the clinical use of inotuzumab ozogamicin during breastfeeding. Because inotuzumab oz …
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM, DeAngelo DJ, Stelljes M, Martinelli G, Liedtke M, Stock W, Gökbuget N, O'Brien S, Wang K, Wang T, Paccagnella ML, Sleight B, Vandendries E, Advani AS. Kantarjian HM, et al. N Engl J Med. 2016 Aug 25;375(8):740-53. doi: 10.1056/NEJMoa1509277. Epub 2016 Jun 12. N Engl J Med. 2016. PMID: 27292104 Free PMC article. Clinical Trial.
METHODS: In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group). ...B …
METHODS: In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either in …
Inotuzumab Ozogamicin.
[No authors listed] [No authors listed] 2024 Jan 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2024 Jan 15. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643242 Free Books & Documents. Review.
Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or relapsed acute lymphoblastic leukemia. Inotuzumab ozogamicin has been linked to frequent serum enzyme elevations during therapy a …
Inotuzumab ozogamicin is a humanized monoclonal antibody-cytotoxin conjugate which is used in the therapy of refractory or rel …
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study.
Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, Liang White J, Sleight B, Vandendries E, Advani AS. Kantarjian HM, et al. Cancer. 2019 Jul 15;125(14):2474-2487. doi: 10.1002/cncr.32116. Epub 2019 Mar 28. Cancer. 2019. PMID: 30920645 Free PMC article. Clinical Trial.
BACKGROUND: Inotuzumab ozogamicin (InO) is an antibody-drug conjugate used for adults with relapsed/refractory B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The INotuzumab Ozogamicin trial to inVestigAte Tolerability and Efficacy (INO-VATE …
BACKGROUND: Inotuzumab ozogamicin (InO) is an antibody-drug conjugate used for adults with relapsed/refractory B-cell precurso …
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD, O'Brien MM. Rubinstein JD, et al. Front Immunol. 2023 Aug 3;14:1237738. doi: 10.3389/fimmu.2023.1237738. eCollection 2023. Front Immunol. 2023. PMID: 37600823 Free PMC article. Review.
Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized monoclonal antibody targeting the cell surface receptor CD22 coupled to a cytotoxic calicheamicin payload via an acid labile linker. ...
Inotuzumab ozogamicin (InO) is an antibody drug conjugate composed of a humanized monoclonal antibody targeting the cell surfa …
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.
Jabbour E, Short NJ, Senapati J, Jain N, Huang X, Daver N, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Montalban Bravo G, Sasaki K, Kadia TM, Khoury J, Wang SA, Haddad FG, Jacob J, Garris R, Ravandi F, Kantarjian HM. Jabbour E, et al. Lancet Haematol. 2023 Jun;10(6):e433-e444. doi: 10.1016/S2352-3026(23)00073-X. Epub 2023 May 12. Lancet Haematol. 2023. PMID: 37187201 Clinical Trial.
BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse disease biology and their inability to tolerate intensive therapy. We aimed to study the long-term outcomes of inotuzumab ozogami …
BACKGROUND: The outcome of older patients with B-cell acute lymphocytic leukaemia is inferior to that in younger patients due to the adverse …
Inotuzumab Ozogamicin: First Global Approval.
Lamb YN. Lamb YN. Drugs. 2017 Sep;77(14):1603-1610. doi: 10.1007/s40265-017-0802-5. Drugs. 2017. PMID: 28819740 Review.
In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly diagnosed B-cell ALL has recently been initiated and inotuzumab ozogamicin is under phase II evaluation in childhood CD22-pos …
In the USA, a phase III trial evaluating inotuzumab ozogamicin in combination with frontline chemotherapy in adults with newly …
Inotuzumab ozogamicin for acute lymphoblastic leukaemia.
[No authors listed] [No authors listed] Aust Prescr. 2019 Aug;42(4):141-142. doi: 10.18773/austprescr.2019.046. Epub 2019 Jun 17. Aust Prescr. 2019. PMID: 31427847 Free PMC article. Review. No abstract available.
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.
Kantarjian H, Ravandi F, Short NJ, Huang X, Jain N, Sasaki K, Daver N, Pemmaraju N, Khoury JD, Jorgensen J, Alvarado Y, Konopleva M, Garcia-Manero G, Kadia T, Yilmaz M, Bortakhur G, Burger J, Kornblau S, Wierda W, DiNardo C, Ferrajoli A, Jacob J, Garris R, O'Brien S, Jabbour E. Kantarjian H, et al. Lancet Oncol. 2018 Feb;19(2):240-248. doi: 10.1016/S1470-2045(18)30011-1. Epub 2018 Jan 16. Lancet Oncol. 2018. PMID: 29352703 Clinical Trial.
BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent activity in relapsed or refractory acute lymphoblastic leukaemia. We aimed to assess the activity and safety of inotuzumab ozogamici …
BACKGROUND: Inotuzumab ozogamicin, an anti-CD22 monoclonal antibody bound to a toxin, calicheamicin, has shown single-agent ac …
Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
Al-Salama ZT. Al-Salama ZT. Target Oncol. 2018 Aug;13(4):525-532. doi: 10.1007/s11523-018-0584-z. Target Oncol. 2018. PMID: 30090971 Review.
Although there was no significant between-group difference in overall survival duration as per the study design, the 2-year survival probability in the inotuzumab ozogamicin arm was twice that in the control arm. Inotuzumab ozogamicin had an acceptable …
Although there was no significant between-group difference in overall survival duration as per the study design, the 2-year survival probabi …
396 results

Searches related to "inotuzumab ozogamicin"